Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,303.10 +8.60 0.06%
S&P 500 1,649.60 -0.91 -0.06%
Nasdaq 3,459.14 -0.27 -0.01%
Ticker Volume Price Price Delta
STOXX 50 2,764.29 -12.49 -0.45%
FTSE 100 6,654.34 -42.45 -0.63%
DAX 8,305.32 -46.66 -0.56%
Ticker Volume Price Price Delta
Nikkei 14,612.50 +128.47 0.89%
Hang Seng 22,618.70 -51.01 -0.23%
S&P/ASX 200 4,983.50 -78.95 -1.56%
  • Exchange: NASDAQ CM
  • Sector: Consumer, Non-cyclical
  • Industry: Biotechnology
  • Sub-Industry: Medical-Biomedical/Gene

Chelsea Therapeutics International Ltd

+ Add to Watchlist

CHTP:US

1.8400 USD 0.0600 3.16%

As of 20:10:00 ET on 05/24/2013.

Company Profile for Chelsea Therapeutics International Ltd (CHTP)

Chelsea Therapeutics International Ltd. is a biopharmaceutical company developing a pipeline of low toxicity antifolate compounds engineered to have anti-inflammatory and anti-tumor activity. The Company's lead candidate is in development as a metabolically inert treatment alternative to Methotrexate for rheumatoid arthritis, psoriasis, and other disorders.

Contact Information

Chelsea Therapeutics International Ltd

3530 Toringdon Way
Suite 200
Charlotte, NC 28277
United States
Phone: 1-704-341-1516
Fax: 1-704-752-1479

Key Executives for Chelsea Therapeutics International Ltd (CHTP)

Joseph G OlivetoInterim CEOWilliam D SchwietermanVP/Chief Medical Officer
L Arthur HewittVP/Chief Scientific OfficerJ Nick RiehleVP:Administration/CFO
Michael J RobertsVP:Business Development

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil